Rac1-IN-2


CAS No. : 701223-06-5

701223-06-5
Price and Availability of CAS No. : 701223-06-5
Size Price Stock
100 mg Get quote
250 mg Get quote
500 mg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-122739
M.Wt: 388.49
Formula: C23H20N2O2S
Purity: >98 %
Solubility:
Introduction of 701223-06-5 :

Rac1-IN-2 is a small-molecule Rac1 inhibitor. Rac1-IN-2 inhibits Rac1-mediated signaling by blocking the binding of active Rac1 to PAK1 (IC50 = 88 nM), exhibits selectivity for Rac1 over Cdc42 and RhoA, and suppresses the proliferation, migration, clonogenicity, and viability of pancreatic cancer cells. Rac1-IN-2 can be used for research on pancreatic cancer[1]. In Vitro:Rac1-IN-2 (compound #6) (0.001-100 μM; 1 h) disrupts Rac1-PAK1 complex formation with an IC50 of 88 nM[1].
Rac1-IN-2 (10 μM; 2 h) inhibits Rac1 activity in CD18/HPAF cells[1].
Rac1-IN-2 (1-50 μM; 2 h) inhibits EGF-induced Rac1 activation in CD18/HPAF cells with an EC50 of 22.4 μM[1].
Rac1-IN-2 (50 μM; 2 h) selectively inhibits Rac1 activity in CD18/HPAF cells without inhibiting Cdc42 or RhoA[1].
Rac1-IN-2 (25 μM; 24-120 h) inhibits the proliferation of Capan1 and CD18/HPAF cells[1].
Rac1-IN-2 (50 μM; 24-48 h) inhibits the migration of Capan1 and CD18/HPAF cells, with maximal wound closure inhibition of approximately 60% and 40%, respectively[1].
Rac1-IN-2 (50 μM; 1 h pre-incubation; 24 h migration) inhibits transwell migration of Capan1 and CD18/HPAF cells[1].
Rac1-IN-2 (7 days) reduces clonogenic survival of Capan1 cells, with little effect on HPNE normal pancreatic ductal cells[1].
Rac1-IN-2 (1.6-100 μM; 7 days) reduces the viability of AsPC-1, Capan1, and CD18/HPAF cells with EC50 values of 14.7, 24.2, and 23.5 μM, respectively[1].

Your information is safe with us.